Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The company's business focus is on the treatment of cancer, infections and autoimmune diseases. The research is based on the company's proprietary drug-delivery technology. The products are sold under separate brands and product development collaborations take place with other players in the industry. The company is headquartered in Uppsala.

Quotes for Double Bond Pharmaceutical International AB

Right Now

+/-
-0.009
%
−7,17%
Latest
0.1165
High
0.1255
Low
0.1165
Volume
850
Turnover (SEK)
100
Market Value (MSEK)
23,9
Time (Latest trade)
2025-09-04 15:39

Board

CEO

  • Igor Lokot

Chairperson of the Board

  • Sanna Rejnlander

Board

  • Igor Lokot
  • Irina Zaitseva
  • Sergey Yanitsky
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Double Bond sitdown

    BeloGal® and SA-033 (svenska)

    BeloGal® and SA-033 (english)

    Aktiespararna intervjuar VD Igor Lokot

    Largest Owners

    Name Capital % Votes % Date
    Igor Lokot 9,01 16,06 2025-06-26
    KSDR Hamberg AB 7,82 7,21 2025-06-26
    Per Ahlström 7,74 7,14 2025-06-26
    Carl Carvalho 4,03 3,72 2025-06-26
    Lars-Åke Börje Flarke 3,41 3,15 2025-06-26
    Avanza Pension 3,01 2,78 2025-06-26
    Investentia AB 2,80 2,58 2025-06-26
    Magnus Hamberg 2,57 2,37 2025-06-26
    Thomas Trumstedt 1,87 1,72 2025-06-26
    Georgi Kalbin 1,75 1,61 2025-06-26
    ** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

    Insider trading

    *Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

    Key Numbers

    *Compiled data from Millistream

    Upcoming reports

    • 2025-09-12 Extra bolagsstämma 2025

    • 2025-11-25 Delårsrapport 2025-Q3

    Annual reports, prospectus etc.